Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Clearmind Medicine Inc. (CMND)
NASDAQ:AMEX Investor Relations:
ir.manitowocfoodservice.com/investor-relations/default.aspx
Company Research
Source: GlobeNewswire
Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced the publication of its patent application under the international Patent Cooperation Treaty (“PCT”) for innovative combinations of Ketamine and N-Acylethanolamines. The patent application was filed as a result of the Company's continuous collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialized pharmaceutical company in the clinical trial phase, dedicated to creating treatments for central nervous system disorders. As part of the collaboration, the two companies are researching combination therapies that integrate SciSparc’s Palmitoylethanolamide (“PEA”) with Clearmind’s innovative psychedelic molecule, 5-methoxy-2-aminoindan (MEAI), aimed at treating addictions,
Show less
Read more
Impact Snapshot
Event Time:
CMND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMND alerts
High impacting Clearmind Medicine Inc. news events
Weekly update
A roundup of the hottest topics
CMND
News
- Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site [Yahoo! Finance]Yahoo! Finance
- Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical SiteGlobeNewswire
- Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy [Yahoo! Finance]Yahoo! Finance
- Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapyGlobeNewswire
- Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD TreatmentGlobeNewswire
CMND
Sec Filings
- 11/20/24 - Form 6-K
- 11/14/24 - Form SC
- 10/10/24 - Form 6-K
- CMND's page on the SEC website